Answer
No, the safety and efficacy of Kisqali (ribociclib) have not been established in children and adolescents under 18 years, and no dosing recommendation can be made.
Sources for this answer
- Kisqali film coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.2 Posology and method of administration · Version 25Document updated
Sources checked